Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that ...

On5, Berenberg upgraded its rating on Eli Lilly and Company (NYSE:LLY) from Hold to Buy and lifted its price target from ...

Berenburg upgrades Eli Lilly stock to Buy from Hold, citing growth prospects fueled by its weight-loss drugs.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. An illustrative graphic projects Eli Lilly's (LLY) stock ...

Eli Lilly shed billions in market value over the past month while its underlying business kept breaking records, and now one major Wall Street firm sees a setup that almost never appears in a stock ...

Eli Lilly (LLY-0.65%) stock has soared in recent years. Part of the reason may be due to the company's broad portfolio of drugs across treatment areas, from neuroscience to cancer and dermatology. But ...

Eli Lilly (LLY) stock gains 2% after Citigroup sets a Street-high $1,600 price target and Berenberg upgrades to Buy, citing ...

Eli Lilly (LLY) stock looks attractive vs. overextended semiconductors, with strong Q2 growth and reasonable PEG. See here ...

Fundamentals, not a stock split, will determine whether the bull case for Eli Lilly continues.

Eli Lilly is scheduled to report earnings Wednesday morning, with traders expecting the drugmaker’s stock could potentially approach last month’s highs following the results.

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.